COMMUNIQUÉS West-GlobeNewswire

Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study
06/08/2025
PRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine Reinforces SomaScan’s strategic position in the high-impact biobank segment and its increasing role in leading [...]
Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress
06/08/2025
– On track to report top-line data from Phase 2 trial in chronic rhinosinusitis with nasal polyps (CRSwNP) in the third quarter of 2025 – – Completed enrollment in Phase 2 trial in severe asthma in June 2025; top-line [...]
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update
06/08/2025
– Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – – Presented ARV-102 SAD and MAD data from the Phase 1 clinical trial in healthy volunteers [...]
Bioventus Reports Second Quarter Financial Results
06/08/2025
Q2 reported revenue of $147.7 million declined 2.4% ; Organic* revenue advanced 6.2% Second quarter diluted earnings per share was $0.11 compared to a diluted loss per share of $0.40 in the prior-year period Non-GAAP [...]
BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies
06/08/2025
Dexmedetomidine demonstrated a significant reduction in stress-induced behaviors, suggesting potential applications of BXCL501 in chronic psychiatric disorders in addition to treatment of acute agitation Leading [...]
Entrada Therapeutics Reports Second Quarter 2025 Financial Results
06/08/2025
-- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in [...]
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
06/08/2025
WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring [...]
Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference
06/08/2025
NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright’s 5 th Annual [...]
Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025
06/08/2025
Company to Host Conference Call at 8:30am ET REHOVOT, Israel, and HOBOKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a [...]
EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments
06/08/2025
– Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest [...]
American Shared Hospital Services Announces Second Quarter Financial Results Conference Call
06/08/2025
Call Scheduled for August 13th at 1:00 PM ET SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery [...]
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
06/08/2025
–European marketing authorization application on track in 2H25 – – PREVAIL Phase 3 CVOT remains on track – – Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England [...]
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/08/2025
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired [...]
MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update
06/08/2025
Conference call today at 9:00 am ET 2Q 2025 revenues of $76.5M, +6% v. 2Q 2024 YTD 2025 revenues of $154.9M, +12% v. YTD 2024 Advanced pipeline: Submitted sBLA for Afrezza ® in pediatric population MNKD-101: NTM global [...]
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
06/08/2025
Strengthens MannKind’s capital structure with flexible, long-term, non-dilutive funding MannKind to receive $75 million in cash at closing DANBURY, Conn. and WESTLAKE VILLAGE, Calif. and NEW YORK, Aug. 06, 2025 (GLOBE [...]
Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine
06/08/2025
Peer-reviewed publication highlights ATI-1701’s robust protection against aerosolized Francisella tularensis exposure in multiple animal models HALIFAX, Nova Scotia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics [...]
Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury
06/08/2025
First patient successfully completes dosing at Toronto General Hospital St. Michael’s Hospital is expected to be the next Canadian clinical site activated Arch is looking for additional clinical sites in North America [...]
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
06/08/2025
WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with [...]
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
06/08/2025
Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo [...]

Pages